Caribou Biosciences Files 8-K
Ticker: CRBU · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001619856
| Field | Detail |
|---|---|
| Company | Caribou Biosciences, INC. (CRBU) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing, 8-k
TL;DR
Caribou Biosciences filed an 8-K on 3/31/26, standard disclosure, no major news yet.
AI Summary
On March 31, 2026, Caribou Biosciences, Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The filing includes an iXBRL 8-K document and exhibits, but no specific financial figures or material events were disclosed in the provided text.
Why It Matters
This filing indicates Caribou Biosciences is providing updates or disclosures as required by the SEC, though the specific content of the update is not detailed in the provided filing information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no disclosed material events or financial changes, indicating low immediate risk.
Key Players & Entities
- Caribou Biosciences, Inc. (company) — Filer of the 8-K report
- 0001619856 (company) — CIK number for Caribou Biosciences, Inc.
- 2026-03-31 (date) — Filing date of the 8-K report
FAQ
What is the primary purpose of this 8-K filing by Caribou Biosciences?
The 8-K filing serves as a Current Report, covering items such as Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as filed on March 31, 2026.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on March 31, 2026, at 08:02:47.
What are the main document types included in this filing?
The filing includes an iXBRL 8-K document, an exhibit (EX-99.1), and various XBRL-related documents such as schema, label, presentation, and instance documents.
Where is Caribou Biosciences, Inc. located based on the filing?
Caribou Biosciences, Inc.'s mailing and business address is listed as 2929 7TH STREET, SUITE 105, BERKELEY CA 94710.
What is the SIC code associated with Caribou Biosciences, Inc.?
The SIC code for Caribou Biosciences, Inc. is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2026-03-31 08:02:47
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global
Filing Documents
- crbu-20260331.htm (8-K) — 27KB
- crbu-20260331xexx991.htm (EX-99.1) — 21KB
- img25401123_0a.jpg (GRAPHIC) — 51KB
- 0001619856-26-000012.txt ( ) — 244KB
- crbu-20260331.xsd (EX-101.SCH) — 2KB
- crbu-20260331_lab.xml (EX-101.LAB) — 23KB
- crbu-20260331_pre.xml (EX-101.PRE) — 13KB
- crbu-20260331_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 31, 2026, Caribou Biosciences, Inc. (the "Company") issued a press release announcing that it received Regenerative Medicine Advanced Therapy ("RMAT") designation for relapsed or refractory multiple myeloma ("r/r MM") from the U.S. Food and Drug Administration ("FDA") for CB-011, the Company's allogeneic anti-BCMA CAR-T cell therapy product candidate. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and also is incorporated by reference into this Item 7.01. The information in this Item 7.01, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing or other document under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing or document, except as shall be expressly set forth by specific reference in any such filing or document.
01 Other Events
Item 8.01 Other Events. On March 31, 2026 , the Company announced that it received RMAT designation for r/r MM from the FDA for CB-011, its allogeneic anti-BCMA CAR-T cell therapy product candidate. CB-011 is currently being evaluated in the Company's ongoing CaMMouflage phase 1 clinical trial.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on March 31, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: March 31, 2026 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer